The p53 family and the hypoxia-inducible factors (HIFs): Determinants of cancer progression

Trends in Biochemical Sciences

Volumn 40, Issue 8, 2015, Pages 425-434

  Amelio, Ivano ^a   Melino, Gerry ^a,b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PROTEIN MDM2; PROTEIN P53; PROTEIN P63; PROTEIN P73; VASCULOTROPIN A; VASCULOTROPIN C; HYPOXIA INDUCIBLE FACTOR 1;

BIOACCUMULATION; CANCER GROWTH; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; GAIN OF FUNCTION MUTATION; GENE EXPRESSION REGULATION; HIF GENE; HIFALPHA GENE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METABOLISM; METASTASIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REVIEW; TP73 GENE; TRANSCRIPTION REGULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; ANIMAL; DISEASE COURSE; GENETICS; NEOPLASM; PATHOLOGY;

ANIMALS; DISEASE PROGRESSION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84937521119     PISSN: 09680004     EISSN: 13624326     Source Type: Journal    
DOI: 10.1016/j.tibs.2015.04.007     Document Type: Review

References (103)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
2. Bieging K.T., et al. Unravelling mechanisms of p53-mediated tumour suppression. Nat. Rev. Cancer 2014, 14:359-370.
3. Graeber T.G., et al. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol. Cell. Biol. 1994, 14:6264-6277.
4. An W.G., et al. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 1998, 392:405-408.
5. Hansson L.O., et al. Two sequence motifs from HIF-1alpha bind to the DNA-binding site of p53. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:10305-10309.
6. Sanchez-Puig N., et al. Binding of natively unfolded HIF-1alpha ODD domain to p53. Mol. Cell 2005, 17:11-21.
7. Blagosklonny M.V., et al. p53 inhibits hypoxia-inducible factor-stimulated transcription. J. Biol. Chem. 1998, 273:11995-11998.
8. Ravi R., et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 2000, 14:34-44.
9. Yu J.L., et al. Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002, 295:1526-1528.
10. Kaluzova M., et al. DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1alpha in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX. Mol. Cell. Biol. 2004, 24:5757-5766.
11. Yang J., et al. Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia. Mol. Cell. Biol. 2009, 29:2243-2253.
12. Kamat C.D., et al. Mutant p53 facilitates pro-angiogenic, hyperproliferative phenotype in response to chronic relative hypoxia. Cancer Lett. 2007, 249:209-219.
13. Lin J., et al. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 1994, 8:1235-1246.
14. Prives C. Signaling to p53: breaking the MDM2-p53 circuit. Cell 1998, 95:5-8.
15. Vassilev L.T., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.
16. Lee Y.M., et al. Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1alpha. Carcinogenesis 2009, 30:1768-1775.
17. Kojima K., et al. p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1alpha-mediated down-regulation of CXCL12. Blood 2011, 118:4431-4439.
18. Choy M.K., et al. PKB/Akt activation inhibits p53-mediated HIF1A degradation that is independent of MDM2. J. Cell. Physiol. 2010, 222:635-639.
19. Chen D., et al. Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function. J. Biol. Chem. 2003, 278:13595-13598.
20. Joshi S., et al. MDM2 regulates hypoxic hypoxia-inducible factor 1alpha stability in an E3 ligase, proteasome, and PTEN-phosphatidylinositol 3-kinase-AKT-dependent manner. J. Biol. Chem. 2014, 289:22785-22797.
21. Yoo Y.G., et al. Novel function of orphan nuclear receptor Nur77 in stabilizing hypoxia-inducible factor-1alpha. J. Biol. Chem. 2004, 279:53365-53373.
22. Bardos J.I., et al. Growth factor-mediated induction of HDM2 positively regulates hypoxia-inducible factor 1alpha expression. Mol. Cell. Biol. 2004, 24:2905-2914.
23. Nieminen A.L., et al. Mdm2 and HIF-1alpha interaction in tumor cells during hypoxia. J. Cell. Physiol. 2005, 204:364-369.
24. Yang A., et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999, 398:714-718.
25. Yang A., et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000, 404:99-103.
26. Venkatanarayan A., et al. IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo. Nature 2015, 517:626-630.
27. Amelio I., et al. TAp73 opposes tumor angiogenesis by promoting hypoxia-inducible factor 1alpha degradation. Proc. Natl. Acad. Sci. U.S.A. 2015, 112:226-231.
28. Senoo M., et al. TAp63gamma (p51A) and dNp63alpha (p73L), two major isoforms of the p63 gene, exert opposite effects on the vascular endothelial growth factor (VEGF) gene expression. Oncogene 2002, 21:2455-2465.
29. Stantic M., et al. TAp73 suppresses tumor angiogenesis through repression of proangiogenic cytokines and HIF-1alpha activity. Proc. Natl. Acad. Sci. U.S.A. 2015, 112:220-225.
30. Balint E., et al. Mdm2 binds p73 alpha without targeting degradation. Oncogene 1999, 18:3923-3929.
31. Fernandez-Alonso R., et al. p73 is required for endothelial cell differentiation, migration and the formation of vascular networks regulating VEGF and TGFbeta signaling. Cell Death Differ. 2015, Published online January 9, 2015. 10.1038/cdd.2014.214.
32. Dulloo I., et al. Hypoxia-inducible TAp73 supports tumorigenesis by regulating the angiogenic transcriptome. Nat. Cell Biol. 2015, 17:511-523.
33. Romano R.A., et al. Delta Np63 knockout mice reveal its indispensable role as a master regulator of epithelial development and differentiation. Development 2012, 139:772-782.
34. Ramsey M.R., et al. FGFR2 signaling underlies p63 oncogenic function in squamous cell carcinoma. J. Clin. Invest. 2013, 123:3525-3538.
35. Chakrabarti R., et al. DeltaNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. Nat. Cell Biol. 2014, 16:1004-1015.
36. Montagner M., et al. SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature 2012, 487:380-384.
37. Memmi E.M., et al. p63 sustains self-renewal of mammary cancer stem cells through regulation of Sonic Hedgehog signaling. Proc. Natl. Acad. Sci. U.S.A. 2015, 112:3499-3504.
38. Bid H.K., et al. DeltaNp63 promotes pediatric neuroblastoma and osteosarcoma by regulating tumor angiogenesis. Cancer Res. 2014, 74:320-329.
39. 2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 1998, 12:149-162.
40. Peng J., et al. The transcription factor EPAS-1/hypoxia-inducible factor 2alpha plays an important role in vascular remodeling. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:8386-8391.
41. Yoshida D., et al. Hypoxia inducible factor 1-alpha regulates of platelet derived growth factor-B in human glioblastoma cells. J. Neuro Oncol. 2006, 76:13-21.
42. Folkman J., et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989, 339:58-61.
43. Du R., et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008, 13:206-220.
44. Leek R.D., Harris A.L. Tumor-associated macrophages in breast cancer. J. Mammary Gland Biol. Neoplasia 2002, 7:177-189.
45. Talks K.L., et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 2000, 157:411-421.
46. Kurose K., et al. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat. Genet. 2002, 32:355-357.
47. Salimath B., et al. Expression of the vascular endothelial growth factor gene is inhibited by p73. Oncogene 2000, 19:3470-3476.
48. Van Meir E.G., et al. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat. Genet. 1994, 8:171-176.
49. Lujambio A., et al. Non-cell-autonomous tumor suppression by p53. Cell 2013, 153:449-460.
50. Calabrese C., et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11:69-82.
51. Beck B., et al. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 2011, 478:399-403.
52. Bar E.E., et al. Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am. J. Pathol. 2010, 177:1491-1502.
53. Hashimoto O., et al. Hypoxia induces tumor aggressiveness and the expansion of CD133-positive cells in a hypoxia-inducible factor-1alpha-dependent manner in pancreatic cancer cells. Pathobiology 2011, 78:181-192.
54. Soeda A., et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 2009, 28:3949-3959.
55. Covello K.L., et al. HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 2006, 20:557-570.
56. Carmeliet P., Jain R.K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 2011, 10:417-427.
57. Marion R.M., et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 2009, 460:1149-1153.
58. Hong H., et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 2009, 460:1132-1135.
59. Li H., et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 2009, 460:1136-1139.
60. Utikal J., et al. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 2009, 460:1145-1148.
61. Kawamura T., et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009, 460:1140-1144.
62. Choi Y.J., et al. miR-34 miRNAs provide a barrier for somatic cell reprogramming. Nat. Cell Biol. 2011, 13:1353-1360.
63. Sarig R., et al. Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells. J. Exp. Med. 2010, 207:2127-2140.
64. Mazumdar J., et al. O2 regulates stem cells through Wnt/beta-catenin signalling. Nat. Cell Biol. 2010, 12:1007-1013.
65. Kaidi A., et al. Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat. Cell Biol. 2007, 9:210-217.
66. Beck B., Blanpain C. Unravelling cancer stem cell potential. Nat. Rev. Cancer 2013, 13:727-738.
67. Unruh A., et al. The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 2003, 22:3213-3220.
68. Birner P., et al. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin. Cancer Res. 2001, 7:1661-1668.
69. Bertout J.A., et al. Heterozygosity for hypoxia inducible factor 1alpha decreases the incidence of thymic lymphomas in a p53 mutant mouse model. Cancer Res. 2009, 69:3213-3220.
70. Semenza G.L. HIF-1: upstream and downstream of cancer metabolism. Curr. Opin. Genet. Dev. 2010, 20:51-56.
71. Papandreou I., et al. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 2006, 3:187-197.
72. Kim J.W., et al. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006, 3:177-185.
73. Berkers C.R., et al. Metabolic regulation by p53 family members. Cell Metab. 2013, 18:617-633.
74. Hu W., et al. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:7455-7460.
75. Maddocks O.D., et al. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 2013, 493:542-546.
76. Giacobbe A., et al. p63 regulates glutaminase 2 expression. Cell Cycle 2013, 12:1395-1405.
77. Velletri T., et al. GLS2 is transcriptionally regulated by p73 and contributes to neuronal differentiation. Cell Cycle 2013, 12:3564-3573.
78. Amelio I., et al. p73 regulates serine biosynthesis in cancer. Oncogene 2014, 33:5039-5046.
79. D'Alessandro A., et al. Metabolic effect of TAp63alpha: enhanced glycolysis and pentose phosphate pathway, resulting in increased antioxidant defense. Oncotarget 2014, 5:7722-7733.
80. Rufini A., et al. TAp73 depletion accelerates aging through metabolic dysregulation. Genes Dev. 2012, 26:2009-2014.
81. Krishnamachary B., Semenza G.L. Analysis of hypoxia-inducible factor 1alpha expression and its effects on invasion and metastasis. Methods Enzymol. 2007, 435:347-354.
82. Zhang H., et al. HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene 2012, 31:1757-1770.
83. Guo F., Zheng Y. Rho family GTPases cooperate with p53 deletion to promote primary mouse embryonic fibroblast cell invasion. Oncogene 2004, 23:5577-5585.
84. Gadea G., et al. Loss of p53 promotes RhoA-ROCK-dependent cell migration and invasion in 3D matrices. J. Cell Biol. 2007, 178:23-30.
85. Freed-Pastor W.A., Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012, 26:1268-1286.
86. Adorno M., et al. A mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009, 137:87-98.
87. Zhang P., et al. Hypoxia-inducible factor 3 is an oxygen-dependent transcription activator and regulates a distinct transcriptional response to hypoxia. Cell Rep. 2014, 6:1110-1121.
88. Keith B., et al. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 2012, 12:9-22.
89. Weissmueller S., et al. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signaling. Cell 2014, 157:382-394.
90. Steder M., et al. DNp73 exerts function in metastasis initiation by disconnecting the inhibitory role of EPLIN on IGF1R-AKT/STAT3 signaling. Cancer Cell 2013, 24:512-527.
91. Fridman J.S., Lowe S.W. Control of apoptosis by p53. Oncogene 2003, 22:9030-9040.
92. Bertout J.A., et al. HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:14391-14396.
93. Amelio I., et al. TAp73 promotes anabolism. Oncotarget 2014, 5:12820-12834.
94. Semenza G.L., et al. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem. 1994, 269:23757-23763.
95. Lu H., et al. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J. Biol. Chem. 2002, 277:23111-23115.
96. Du W., et al. TAp73 enhances the pentose phosphate pathway and supports cell proliferation. Nat. Cell Biol. 2013, 15:991-1000.
97. Jiang P., et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat. Cell Biol. 2011, 13:310-316.
98. Zhao F., et al. Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming. Oncogene 2010, 29:2962-2972.
99. Contractor T., Harris C.R. p53 negatively regulates transcription of the pyruvate dehydrogenase kinase Pdk2. Cancer Res. 2012, 72:560-567.
100. Jiang P., et al. Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence. Nature 2013, 493:689-693.
101. Tomasini R., et al. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev. 2008, 22:2677-2691.
102. Guo X., et al. TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat. Cell Biol. 2009, 11:1451-1457.
103. Wilhelm M.T., et al. Isoform-specific p73 knockout mice reveal a novel role for delta Np73 in the DNA damage response pathway. Genes Dev. 2010, 24:549-560.